Clinical Trials
16 trialsNCT04348747 2026-05-11
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT02896335 2026-03-12
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT06822543 2025-09-29
TROPICAL-1
Latin American Cooperative Oncology Group
Phase 2 Recruiting
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT02886585 2024-03-12
Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT05255666 2023-07-11
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Washington University School of Medicine
Phase 2 Withdrawn
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02085070 2021-03-24
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Yale University
Phase 2 Completed